Everolimus has also been reported to suppress mTORC2 and the AKT and ERK pathways in AML at doses approaching 20 nM [7], which is the concentration range achieved by the everolimus/azole combination in the current study (Figure 2). The gene discussed is AKT1; the disease is acute myeloid leukemia.